-
11.
公开(公告)号:US20070185324A1
公开(公告)日:2007-08-09
申请号:US11643261
申请日:2006-12-20
申请人: Frenel De Morin , Jian Chen , Elizabeth Doherty , Stephen Hitchcock , Qi Huang , Joseph Kim , Gang Liu , Thomas Nixey , Nick Paras , Jeffrey Petkus , Daniel Retz , Adrian Smith , Andrew Tasker , Jiawang Zhu
发明人: Frenel De Morin , Jian Chen , Elizabeth Doherty , Stephen Hitchcock , Qi Huang , Joseph Kim , Gang Liu , Thomas Nixey , Nick Paras , Jeffrey Petkus , Daniel Retz , Adrian Smith , Andrew Tasker , Jiawang Zhu
IPC分类号: A61K31/541 , A61K31/5377 , C07D417/02 , C07D403/02
CPC分类号: C07D401/14 , C07D239/84 , C07D239/95 , C07D401/04 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04
摘要: The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R1 is and A1, A2, A3, A4, X, Z, Z′, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
摘要翻译: 本发明包括能够调节Raf激酶的新一类化合物,因此可用于治疗Raf激酶介导的疾病,包括黑素瘤,肿瘤和其它癌症相关病症。 这些化合物具有通式I,其中R 1是和A 1,A 2,A 3,A 3, X,Z,Z',R 1,R 2,R 3,R 3, 本文定义了R 5,R 5和R 6。 本发明还包括药物组合物,用于治疗Raf激酶介导的疾病的方法,以及可用于制备本发明化合物的中间体和方法。
-
公开(公告)号:US20060235036A1
公开(公告)日:2006-10-19
申请号:US11406437
申请日:2006-04-17
申请人: Elizabeth Doherty , Hongyu Liao , Mark Norman , Daniel Retz
发明人: Elizabeth Doherty , Hongyu Liao , Mark Norman , Daniel Retz
IPC分类号: A61K31/506 , A61K31/501 , C07D403/14
CPC分类号: C07D417/14 , C07D401/14 , C07D403/12
摘要: Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.
-